Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc. is a biotechnology company focused on cellular therapies intended to promote immune tolerance in organ transplantation. Its lead investigational candidate, FCR001, is a donor-derived cell therapy studied in kidney transplant recipients. The company’s work spans cell therapy development, transplant medicine, immunology, and clinical research. FCR001 is investigational and is not an approved treatment.